SCHEMBL22493918

SCHEMBL22493918

O=C(O)Cc1cc2cccc3ccc4cccc1c4c32

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 1/20 0.56
KMT2A Q03164 4/20 0.55
MEN1 O00255 3/20 0.55
KDM4E B2RXH2 5/20 0.48
ALDH1A1 P00352 5/20 0.47
CYP1A2 P05177 4/20 0.47
HPGD P15428 4/20 0.47
HSD17B10 Q99714 3/20 0.47
GLA P06280 2/20 0.47
POLB P06746 1/20 0.47
CYP2D6 P10635 1/20 0.47
ERBB2 P04626 1/20 0.46
FYN P06241 1/20 0.46
MAOA P21397 1/20 0.46
ACHE P22303 1/20 0.46
AHR P35869 1/20 0.46
AKR1B1 P15121 3/20 0.46
GAA P10253 1/20 0.44
THRB P10828 1/20 0.41
MAPT P10636 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1275568 0.86 KMT2A (0.68) TDP1KMT2AMEN1KDM4EALDH1A1
SCHEMBL29521196 0.86 KMT2A (0.68) TDP1KMT2AMEN1KDM4EALDH1A1
SCHEMBL9334268 0.81 KMT2A (0.80) TDP1KMT2AMEN1KDM4EALDH1A1
SCHEMBL975512 0.80 CYP1A2 (0.53) TDP1KMT2AMEN1KDM4EALDH1A1
SCHEMBL28055564 0.79 TDP1 (0.56) TDP1KMT2AMEN1KDM4EALDH1A1
SCHEMBL14873480 0.79 KDM4E (0.51) TDP1KMT2AMEN1KDM4EALDH1A1
SCHEMBL498807 0.79 KMT2A (0.71) TDP1KMT2AMEN1KDM4EALDH1A1
SCHEMBL975510 0.78 CYP1A2 (0.52) TDP1KMT2AMEN1KDM4EALDH1A1
SCHEMBL13713632 0.78 AKR1B1 (0.58) TDP1KMT2AMEN1KDM4EALDH1A1
SCHEMBL27705873 0.78 CYP1A2 (0.52) TDP1KMT2AMEN1KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3727435-B1 BIVALENT NUCLEIC ACID LIGANDS AND USES THEREFOR UNIV CARNEGIE MELLON (US) 2026-02-18 EP disclosed
CN-111757935-B Bivalent nucleic acid ligands and uses thereof 卡耐基梅隆大学 2025-02-21 CN disclosed
US-11859242-B2 Template-directed nucleic acid targeting compounds CARNEGIE MELLON UNIVERSITY (US) 2024-01-02 US disclosed
US-20200340044-A1 Template-Directed Nucleic Acid Targeting Compounds CARNEGIE MELLON UNIVERSITY 2020-10-29 US disclosed
EP-3728206-A1 TEMPLATE-DIRECTED NUCLEIC ACID TARGETING COMPOUNDS CARNEGIE MELLON UNIVERSITY (US) 2020-10-28 EP disclosed
EP-3727435-A1 BIVALENT NUCLEIC ACID LIGANDS AND USES THEREFOR CARNEGIE MELLON UNIVERSITY (US) 2020-10-28 EP disclosed
CN-111801317-A Template-directed nucleic acid-targeting compounds 卡耐基梅隆大学 2020-10-20 CN disclosed
CN-111757935-A Bivalent nucleic acid ligand and use thereof 卡耐基梅隆大学 2020-10-09 CN disclosed
US-20200318195-A1 Bivalent Nucleic Acid Ligands and Uses Therefor CARNEGIE MELLON UNIVERSITY 2020-10-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200340044-A1 Template-Directed Nucleic Acid Targeting Compounds TARDBP, HTT, TRDMT1 TDP1 64/4885KMT2A 846/4885MEN1 1494/4885
US-11859242-B2 Template-directed nucleic acid targeting compounds TARDBP, HTT, TRDMT1 TDP1 64/4885KMT2A 846/4885MEN1 1494/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.